An exciting postdoctoral Fellowship opportunity is available for a highly motivated candidate in the laboratory of Dr. Chava Kimchi-Sarfaty, within the Office of Tissues and Advanced Therapies (OTAT), Center for Biologics Evaluation and Research (CBER). The Center for Biologics Evaluation and Research (CBER), FDA regulates biological products for human use under applicable federal laws, including the Public Health Service Act and the Federal Food, Drug and Cosmetic Act. CBER protects and advances the public health by ensuring that biological products are safe and effective and available to those who need them. The Office of Tissues and Advanced Therapies (OTAT), plans and conducts research related to the development, manufacture, and testing of cellular, tissue, gene therapy products, and plasma protein biologics and recombinant analogues. The Office also reviews and evaluates the safety and efficacy of cellular, tissue, and gene therapy products that have a major impact on public health.
The Fellowship project is focused on the mechanisms by which non-synonymous and synonymous mutations impact protein biogenesis. The candidate will employ a variety of laboratory based tools to assess transcriptional, translational and posttranslational effects on recombinant model proteins (e.g. blood proteins, antibodies). The selected candidate will perform the following functions as a part of this project:
- Perform and analyze laboratory experiments;
- Maintain records of laboratory work;
- Participate in research grant and publication writing;
- Present in internal and national meetings; and
- Collaborate on projects as necessary.
This is a contract Fellowship (or guest appointment) through the Oak Ridge Institute for Science and Education (ORISE). The ORISE Research Participation Programs at FDA are educational and training programs designed to provide college students, recent graduates, and university faculty opportunities to participate in project-specific FDA research and developmental activities.
Postgraduate appointments are normally full-time, for one year, and renewable for up to three additional years, subject to project needs, performance, and funding availability. Proof of health insurance is required for participation. Participants do not become employees of FDA or the program administrator, and there are no fringe benefits paid. For more information regarding the ORISE program, eligibility, or definition of a guest appointment, please refer to the ORISE website at: https://orise.orau.gov/fda/applicants/.
QUALIFICATIONS: The ideal candidate: 1) should have received their Ph.D. in molecular or cell biology, or a closely related field within five years of the desired start date or expect to complete all degree requirements prior to the desired start date; and 2) should be legally authorized to work in the United States.
MONTHLY STIPEND: Program participants are paid a monthly stipend. No salaries or fringe benefits paid. Participants do not earn sick leave or annual leave time; although the host facility can permit occasional absences without reduction of the stipend payment or termination of the appointment.
LOCATION: The laboratory is located on the FDA campus in Silver Spring, Maryland which offers an excellent environment for professional development.
HOW TO APPLY: Submit electronic resume or curriculum vitae (including academic history, employment history, relevant experiences, and publication list), two educational or professional references, and educational transcripts to Dr. Chava Kimchi-Sarfaty at Chava.Kimchi-Sarfaty@fda.hhs.gov. All applications and supporting documentation must be received November 30, 2017. Please reference Job Code: OTAT-18-0002-CCP.
DEPARTMENT OF HEALTH AND HUMAN SERVICES IS AN EQUAL OPPORTUNITY EMPLOYER
SMOKE FREE ENVIRONMENT
SMOKE FREE ENVIRONMENT
.png)
No hay comentarios:
Publicar un comentario